FDA Greenlights Oral Wegovy Pill with 16.6% Weight Loss, Launch Set for January
On December 23, 2025, FDA approved Novo Nordisk’s oral Wegovy pill, which yielded 16.6% mean weight loss after 64 weeks compared with 12.4% for Lilly’s orforglipron. Novo expects US sales to start in January 2026, giving it a multimonth head start before Lilly’s anticipated approval in late March.
1. FDA Approval Spurs Immediate Share Recovery
On December 23, 2025, the U.S. Food and Drug Administration granted approval for Novo Nordisk’s oral Wegovy pill, triggering a 7% surge in the company’s shares on that day. This marks the first FDA approval of an oral GLP-1 weight-loss therapy and follows a challenging year in which Novo’s stock delivered a total return of –40% through December 30. Investors have reacted positively to the unexpected catalyst, viewing the pill’s January 2026 U.S. launch as a pivotal step toward restoring market confidence and revenue growth.
2. Efficacy and First-Mover Advantage Over Eli Lilly
Clinical trial data presented by Novo Nordisk show that patients taking oral Wegovy achieved an average 16.6% body-weight reduction at 64 weeks, compared with a 12.4% average loss in Eli Lilly’s orforglipron study at 72 weeks. Adjusted for placebo and adherence, the respective figures stand at roughly 11.2% versus 9.1%. With oral Wegovy expected to reach pharmacies in January—nearly three months before Lilly’s anticipated late-March approval—Novo secures a critical window to capture patients who prefer pills over injections and to entrench prescribing habits among healthcare providers.
3. Sales Growth Slide Highlights Urgent Need for New Product
Novo’s most recent quarterly report revealed a stark deceleration in weight-loss drug sales growth, from 21% year-over-year in Q3 2024 to just 5% in Q3 2025. This contrasts sharply with Lilly’s 54% growth driven by Zepbound (tirzepatide) following its FDA approval in November 2023. By February 2025, Lilly had overtaken Novo in U.S. market share for incretin-analog therapies. The oral Wegovy pill is poised to reverse this trend, but its commercial impact will be measured against the rapid adoption of competing products and the company’s ability to sustain momentum.
4. 2026 Outlook Hinges on Pill Uptake and Pipeline Innovations
Analysts project that oral Wegovy could contribute up to $2.5 billion in U.S. sales during its first full year on the market, helping to offset the slide in injectable semaglutide revenue. Longer term, Novo Nordisk’s late-stage candidate CagriSema—which delivered 22.7% mean weight loss at 68 weeks in phase 3 trials—represents the next potential growth driver. Investor focus for 2026 will center on monthly prescription volumes for oral Wegovy, real-world adherence data and the timing of CagriSema’s regulatory filings, all key to challenging Lilly’s expanding lead in the weight-loss segment.